E. Brunt

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease

A. Korczyn, W. Poewe, J. Larsen, 1999, Neurology.

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study

D. Brooks, A. Korczyn, W. Poewe, 1998, Movement disorders : official journal of the Movement Disorder Society.

Paroxysmal kinesigenic dyskinesia and infantile convulsions

J. Jankovic, M. Leppert, A. Bowcock, 2000, Neurology.

Abstracts Second Congress of the European Society for Clinical Neuropharmacology

K. Jellinger, L. Iversen, K. Lesch, 1995, Journal of Neural Transmission / General Section JNT.

Spinocerebellar Ataxia Type 7 (SCA7): First Report of a Systematic Neuropathological Study of the Brain of a Patient with a Very Short Expanded CAG‐Repeat

H. Heinsen, L. Schöls, U. Rüb, 2005, Brain pathology.

The Safety of Ropinirole, a Selective Nonergoline Dopamine Agonist, in Patients with Parkinson's Disease

D. Brooks, A. Korczyn, W. Poewe, 1998, Clinical neuropharmacology.

Botulinum toxin versus trihexyphenidyl in cervical dystonia

M. H. Prins, J. Snoek, T. V. van Weerden, 1996, Neurology.

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by l-dopa

D. Brooks, A. Korczyn, J. Montastruc, 2002, Journal of Neural Transmission.